Tvardi Therapeutics, Inc. (TVRD)

NASDAQ: TVRD · Real-Time Price · USD
24.61
-0.60 (-2.38%)
At close: Jun 27, 2025, 4:00 PM
24.45
-0.16 (-0.65%)
After-hours: Jun 27, 2025, 5:55 PM EDT

Company Description

Tvardi Therapeutics, Inc., a clinical-stage biopharmaceutical company, engages in the development of novel, oral, and small molecule therapies targeting STAT3 to treat fibrosis-driven diseases with significant unmet need in the United States.

The company's lead product candidates include TTI-101, which is in Phase 2 clinical development for fibrosis-driven diseases with an initial focus on idiopathic pulmonary fibrosis (IPF), and hepatocellular carcinoma (HCC); and TTI-109, an oral, small molecule STAT3 inhibitor which is in pre-clinical stage.

Tvardi Therapeutics, Inc. was founded in 2017 and is based in Sugar Land, Texas.

Tvardi Therapeutics, Inc.
Tvardi Therapeutics logo
Country United States
Founded 2017
Industry Biotechnology
Sector Healthcare
CEO Imran Alibhai

Contact Details

Address:
3 Sugar Creek Center Boulevard, Suite 525
Sugar Land, Texas 77478
United States
Phone 713 489 8654
Website tvarditherapeutics.com

Stock Details

Ticker Symbol TVRD
Exchange NASDAQ
Stock Type Common Stock
Reporting Currency USD
CIK Code 0001742947
CUSIP Number 140755307
ISIN Number US1407553072

Key Executives

Name Position
Dr. Imran Alibhai Ph.D. Chief Executive Officer and Director
Wallace Hall Jr. Founder, President and Director
David J. Tweardy M.D. Co-Founder and Scientific Advisory Board Member
Dr. Ronald A. DePinho M.D. Co-Founder and Chairman of Scientific Advisory Board
Dr. Michael T. Lewis Ph.D. Co-Founder and Scientific Advisory Board Member
Dan Conn J.D., M.B.A. Chief Financial Officer
Dr. Jeffrey Larson DABT, Ph.D. Senior Vice President of Research & Development
Dr. John Kauh M.D. Chief Medical Officer
Stephen O'Brien CPA Vice President of Finance and Corporate Controller
Dr. Yixin Chen Ph.D. Vice President of CMC